RAD140 30 mg 30 Tabs Odin Pharma

RAD140 30 mg 30 tabs Odin Pharma provides Testolone, a non-steroidal selective androgen receptor modulator (SARM), in pharmaceutical-grade oral tablets dosed at 30 mg each for precise research applications. Packaged in sealed HDPE bottles with child-resistant caps, this product features laser-etched scoring for accurate division and desiccant protection for humidity control. Positioned for sophisticated adult researchers and compound collectors, RAD140 offers high binding affinity to androgen receptors (Ki ~7 nM) with tissue-selective properties distinguishing it from traditional anabolic agents. Available through authorized research channels, it supports compliant acquisition for qualified buyers maintaining reference standards.

Brand & Manufacturer Information

Odin Pharma specializes in performance research chemicals including SARMs, peptides, and novel modulators, producing RAD140 tablets under controlled laboratory conditions with emphasis on purity exceeding 99% via HPLC verification. The brand prioritizes uniform tablet compression (250-300 mg total weight) and consistent active distribution, earning recognition among research communities requiring reproducible SARM formulations. Odin Pharma’s RAD140 distinguishes itself through elevated 30 mg dosing versus common 10-20 mg research standards, positioning it for advanced reference collections valuing high-potency, single-source purity documentation.

Active Compound Information

Testolone (RAD140, C20H16ClN5O2) constitutes the active SARM in these 30 mg Odin Pharma tablets, featuring a unique oxadiazole-trifluoroacetamide scaffold delivering exceptional AR selectivity (Ki 7 nM) versus PR/GR/MR receptors. Unlike steroidal anabolics, RAD140 demonstrates tissue-specific AR agonism favoring anabolic over androgenic pathways while exhibiting neuroprotective properties in preclinical hippocampal models. This non-aromatizing, 16-24 hour half-life compound resists 5α-reduction and maintains oral bioavailability through enteric-protected tablet matrix, distinguishing it within the SARM pharmacophore family originally developed for sarcopenia and breast cancer cachexia research.

Product Specifications

RAD140 30 mg 30 tabs Odin Pharma specifications include: 30 mg Testolone per oval, white, biconvex, laser-scored tablet in 30-count HDPE bottle with foil induction seal and 60cc desiccant. Tablets measure 9mm diameter, 250mg total weight, with 1:10 excipient:active ratio using pharmaceutical microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. Bottles feature lot-specific laser etching, 24-month shelf life from manufacture, and ambient storage stability (-20°C to 25°C). Scored design enables 15 mg precision division for research titration protocols.

Quality Control & Testing Standards

Odin Pharma subjects RAD140 tablets to multi-stage QC including raw API identity confirmation (HPLC, MS), content uniformity testing per USP <905>, dissolution profiling (Q=80% in 30 min, pH 6.8 phosphate buffer), and microbial limits verification. Finished lots receive CoA documentation certifying >99% purity, heavy metals <10 ppm, and residual solvents compliant with ICH Q3C guidelines. Independent third-party assays published by research communities consistently validate declared 30 mg potency (±3% variance), with tablet hardness maintained at 5-7 kp for swallowability and scoring integrity.

Intended Use & Market Positioning

RAD140 30 mg Odin Pharma tablets target advanced research collections, preclinical androgen receptor binding studies, and SARM pharmacodynamic reference standards for institutional laboratories. Positioned as high-potency Testolone exceeding standard 10-20 mg research doses, these tablets support dose-response modeling, AR selectivity profiling, and tissue-specific modulator comparisons versus steroidal benchmarks. The elevated concentration facilitates microdosing protocols (5-15 mg increments via scoring) while maintaining bulk economical pricing for longitudinal research spanning 4-12 week observation periods.

Packaging, Storage & Handling

Odin Pharma RAD140 ships in temperature-controlled secondary packaging protecting HDPE bottles during transit, with each container featuring tamper-evident foil seal, child-resistant closure, and printed desiccant sachet absorbing ambient moisture. Tablets maintain stability at 15-25°C (59-77°F) away from direct sunlight and humidity extremes; refrigeration optional but avoid freezing to preserve enteric coating integrity. Handle with clean, dry implements; store upright to minimize tablet migration within bottle. Opened bottles remain viable 90 days post-induction seal breach when properly resealed.

Purchasing & Availability Information

RAD140 30 mg 30 tabs Odin Pharma stocks reliably through specialized research chemical platforms offering encrypted checkout, cryptocurrency conversion, and tracked international express shipping. Bulk laboratory pricing activates at 10+ bottle quantities with CoA batch documentation included. Vendors maintain 30-60 day ambient stability for ground/priority transit, with expedited thermal packaging available for tropical destinations. Live inventory transparency and lot reservation systems support institutional procurement planning and continuity across research phases.

Legal & Regulatory Disclaimer

RAD140 (Testolone) exists in regulatory gray area as investigational Phase II SARM lacking FDA/EMA approval for human medical use, classified as research chemical requiring institutional oversight in controlled jurisdictions. Buyers assume complete responsibility verifying compliance with local chemical control statutes, institutional biosafety protocols, and import/export documentation where applicable. Odin Pharma supplies strictly for bona fide laboratory investigation, in vitro receptor binding assays, and pharmacokinetic reference; no human/veterinary administration authorized or implied. Professional ethical review mandatory prior to experimental protocol initiation.